Holen Sie sich die Stockscreener-App
64.34
0.24%
0.155
Handel nachbörslich:
64.31
-0.03
-0.05%
Schlusskurs vom Vortag:
$64.19
Offen:
$64.19
24-Stunden-Volumen:
1.11M
Relative Volume:
0.75
Marktkapitalisierung:
$12.70B
Einnahmen:
$2.75B
Nettoeinkommen (Verlust:
$322.29M
KGV:
38.53
EPS:
1.67
Netto-Cashflow:
$300.88M
1W Leistung:
+0.72%
1M Leistung:
-4.07%
6M Leistung:
-25.94%
1J Leistung:
-28.35%
1-Tages-Spanne:
$63.87
$64.71
1-Wochen-Bereich:
$61.71
$64.71
52-Wochen-Spanne:
$60.63
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Vergleichen Sie BMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
64.34 | 12.70B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
Robeco Institutional Asset Management B.V. Sells 124,092 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
3 Reasons Growth Investors Will Love BioMarin (BMRN) - Yahoo Finance Australia
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET - Marketscreener.com
BioMarin Earnings Call: CEO Alexander Hardy to Present Strategic Vision & 2024 Results - StockTitan
Prediction: This Pharma Stock Will Be the Best Performer in 2025 - 24/7 Wall St.
abrdn plc Acquires 168,121 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Zacks.com featured highlights BioMarin, Cheesecake Factory, Leidos and The Ensign - Yahoo Finance
18,939 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by Mediolanum International Funds Ltd - MarketBeat
Level Wealth Management LLC Invests $627,000 in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Swedbank AB Has $28.40 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BofA Adjusts Price Target on BioMarin Pharmaceutical to $99 From $100 -February 03, 2025 at 10:27 am EST - Marketscreener.com
Top 10 Takeover Targets of 2025 - Genetic Engineering & Biotechnology News
Is BioMarin Pharmaceutical (BMRN) the Best Depressed Stock to Invest in Now? - Insider Monkey
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now? - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Atomi Financial Group Inc. - Defense World
12 Best Depressed Stocks to Invest in Now - Insider Monkey
Merit Financial Group LLC Invests $317,000 in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy - Seeking Alpha
BioMarin turns to ex-Roche dealmaker James Sabry to build ‘next version’ of 27-year-old company - Endpoints News
Why Is Andreas Halvorsen Bullish On BioMarin Pharmaceutical Inc. (BMRN) Now? - Yahoo Finance
Zacks.com featured highlights include BioMarin, Amazon.com, Leidos and The Ensign - Yahoo Finance
Brokers Offer Predictions for BMRN FY2025 Earnings - Defense World
Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks - Insider Monkey
Cantor Fitzgerald Predicts BMRN FY2025 Earnings - MarketBeat
Fort Washington Investment Advisors Inc. OH Sells 12,170 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Sabry Lays Out BioMarin’s New Business Development Plan - News & Insights
Earnings are growing at BioMarin Pharmaceutical (NASDAQ:BMRN) but shareholders still don't like its prospects - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025 - Insider Monkey
Here is Why Growth Investors Should Buy BioMarin (BMRN) Now - Yahoo Finance
10 Under-the-Radar Stocks with Massive Upside for 2025 - Insider Monkey
Avanza Fonder AB Takes Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Head to Head Comparison: BioMarin Pharmaceutical (NASDAQ:BMRN) and Acura Pharmaceuticals (OTCMKTS:ACUR) - Defense World
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Sees Large Decrease in Short Interest - MarketBeat
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Down 3%Should You Sell? - MarketBeat
BioMarin Pharmaceutical Target of Unusually High Options Trading (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Sees Unusually Large Options Volume (NASDAQ:BMRN) - Defense World
BioMarin stock touches 52-week low at $60.77 amid challenges - MSN
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 1-Year LowShould You Sell? - MarketBeat
BioMarin files UPC’s first pharma infringement suit in over three months - IAM
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Simply Wall St
Assenagon Asset Management S.A. Grows Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Wedmont Private Capital Makes New $430,000 Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Down 3%What's Next? - MarketBeat
UTHR: 3 Niche Biotech Stocks Redefining Innovation - StockNews.com
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
5 Biotech Stocks Worth Adding to Your Portfolio in 2025 - Yahoo Finance
Goldman Sachs maintains Buy on BioMarin shares - Investing.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $94.20 Consensus Target Price from Analysts - MarketBeat
BioMarin sues Ascendis Pharma over patent infringement By Investing.com - Investing.com Canada
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):